Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Germany Cell Therapy Manufacturing Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
4.2.2. By Source of Cell (Autologous, Allogenic)
4.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
4.2.4. By Application (Oncology, Cardiovascular Diseases, Orthopaedic Diseases, Others)
4.2.5. By Source (In-House, Contract Manufacturing)
4.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
4.2.7. By Company (2022)
4.2.8. By Region
4.3. Market Map
4.3.1. By Therapy
4.3.2. By Source of Cell
4.3.3. By Application
4.3.4. By Scale of Operation
4.3.5. By Source
4.3.6. By End User
4.3.7. By Region
5. Western Germany Cell Therapy Manufacturing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy
5.2.2. By Source of Cell
5.2.3. By Application
5.2.4. By Scale of Operation
5.2.5. By Source
5.2.6. By End User
6. Central Germany Cell Therapy Manufacturing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy
6.2.2. By Source of Cell
6.2.3. By Application
6.2.4. By Scale of Operation
6.2.5. By Source
6.2.6. By End User
7. Eastern Germany Cell Therapy Manufacturing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy
7.2.2. By Source of Cell
7.2.3. By Application
7.2.4. By Scale of Operation
7.2.5. By Source
7.2.6. By End User
8. Rest of Germany Cell Therapy Manufacturing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Source of Cell
8.2.3. By Application
8.2.4. By Scale of Operation
8.2.5. By Source
8.2.6. By End User
9. Market Dynamics
9.1. Drivers
9.2. Challenges
10. Market Trends & Developments
10.1. Recent Developments
10.2. Product Launches
10.3. Mergers & Acquisitions
11. Germany Cell Therapy Manufacturing Market: SWOT Analysis
12. Porter’s Five Forces Analysis
12.1. Competition in the Industry
12.2. Potential of New Entrants
12.3. Power of Suppliers
12.4. Power of Customers
12.5. Threat of Substitute Product
13. Competitive Landscape
13.1. Novartis AG
13.1.1. Business Overview
13.1.2. Company Snapshot
13.1.3. Products & Services
13.1.4. Current Capacity Analysis
13.1.5. Financials (In case of listed)
13.1.6. Recent Developments
13.1.7. SWOT Analysis
13.2. F.Hoffmann La Roche AG
13.3. Gilead Sciences, Inc.
13.4. Thermo Fischer Scientific, Inc.
13.5. Catalent, Inc.
13.6. JSR Life Sciences LLC (KBI Biopharma Inc)
13.7. Waisman Center (Waisman Biomanufacturing)
13.8. Cell and Gene Therapy Catapult
13.9. Merck KGaA
13.10. Lonza Group
14. Strategic Recommendations
15. About Us & Disclaimer